Laura Maggino1, Giuseppe Malleo1, Stefano Crippa2, Massimo Falconi2, Roberto Salvia3, Giulio Belfiori2, Sara Nobile1, Giulia Gasparini2, Gabriella Lionetto1, Claudio Luchini4, Paola Mattiolo4, Marco Schiavo-Lena5, Claudio Doglioni5, Aldo Scarpa4, Claudio Bassi1. 1. Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, University of Verona Hospital Trust, G.B. Rossi Hospital, Verona, Italy. 2. Unit of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. 3. Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, University of Verona Hospital Trust, G.B. Rossi Hospital, Verona, Italy. roberto.salvia@univr.it. 4. Department of Diagnostics and Public Health, Section of Pathology, University of Verona Hospital Trust, Verona, Italy. 5. Division of Pathology, Pancreas Translational and Clinical Research Center, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
Abstract
BACKGROUND: Data on recurrence after post-neoadjuvant pancreatectomy are scant. This study investigated the incidence and pattern of recurrence in patients with initially resectable and borderline resectable pancreatic ductal adenocarcinoma who received post-neoadjuvant pancreatectomy. Furthermore, preoperative predictors of recurrence-free survival (RFS) and their interactions were determined. PATIENTS AND METHODS: Patients undergoing post-neoadjuvant pancreatectomy at two academic facilities between 2013 and 2017 were analyzed using standard statistics. The possible interplay between preoperative parameters was scrutinized including interaction terms in multivariable Cox models. RESULTS: Among 315 included patients, 152 (48.3%) were anatomically resectable. The median RFS was 15.7 months, with 1- and 3-year recurrence rates of 41.9% and 74.2%, respectively. Distant recurrence occurred in 83.3% of patients, with lung-only patterns exhibiting the most favorable prognostic outlook. Normal posttreatment CA19.9, ΔCA19.9 (both in patients with normal and elevated baseline levels), and posttreatment tumor size were associated with RFS. Critical thresholds for ΔCA19.9 and tumor size were set at 50% and 20 mm, respectively. Interaction between ΔCA19.9 and posttreatment CA19.9 suggested a significant risk reduction in patients with elevated values when ΔCA19.9 exceeded 50%. Moreover, posttreatment tumor size interacted with posttreatment CA19.9 and ΔCA19.9, suggesting an increased risk in the instance of elevated posttreatment CA19.9 values and a protective effect associated with CA19.9 response in patients with tumor size >20 mm. CONCLUSION: Recurrence following post-neoadjuvant pancreatectomy is common. Preoperative tumor size <20 mm, normal posttreatment CA19.9 and ΔCA19.9 > 50% were associated with longer RFS. These variables should not be taken in isolation, as their interaction significantly modulates the recurrence risk.
BACKGROUND: Data on recurrence after post-neoadjuvant pancreatectomy are scant. This study investigated the incidence and pattern of recurrence in patients with initially resectable and borderline resectable pancreatic ductal adenocarcinoma who received post-neoadjuvant pancreatectomy. Furthermore, preoperative predictors of recurrence-free survival (RFS) and their interactions were determined. PATIENTS AND METHODS: Patients undergoing post-neoadjuvant pancreatectomy at two academic facilities between 2013 and 2017 were analyzed using standard statistics. The possible interplay between preoperative parameters was scrutinized including interaction terms in multivariable Cox models. RESULTS: Among 315 included patients, 152 (48.3%) were anatomically resectable. The median RFS was 15.7 months, with 1- and 3-year recurrence rates of 41.9% and 74.2%, respectively. Distant recurrence occurred in 83.3% of patients, with lung-only patterns exhibiting the most favorable prognostic outlook. Normal posttreatment CA19.9, ΔCA19.9 (both in patients with normal and elevated baseline levels), and posttreatment tumor size were associated with RFS. Critical thresholds for ΔCA19.9 and tumor size were set at 50% and 20 mm, respectively. Interaction between ΔCA19.9 and posttreatment CA19.9 suggested a significant risk reduction in patients with elevated values when ΔCA19.9 exceeded 50%. Moreover, posttreatment tumor size interacted with posttreatment CA19.9 and ΔCA19.9, suggesting an increased risk in the instance of elevated posttreatment CA19.9 values and a protective effect associated with CA19.9 response in patients with tumor size >20 mm. CONCLUSION: Recurrence following post-neoadjuvant pancreatectomy is common. Preoperative tumor size <20 mm, normal posttreatment CA19.9 and ΔCA19.9 > 50% were associated with longer RFS. These variables should not be taken in isolation, as their interaction significantly modulates the recurrence risk.
Authors: Chad A Barnes; Mohammed Aldakkak; Kathleen K Christians; Callisia N Clarke; Kulwinder Dua; Ben George; Paul S Ritch; Mandana Kamgar; William A Hall; Naveen Kulkarni; Beth A Erickson; Douglas B Evans; Susan Tsai Journal: Surgery Date: 2020-07-05 Impact factor: 3.982
Authors: F G Uzunoglu; M-N Welte; F Gavazzi; L Maggino; J Perinel; R Salvia; M Janot; M Reeh; D Perez; M Montorsi; A Zerbi; M Adham; W Uhl; C Bassi; J R Izbicki; G Malleo; M Bockhorn Journal: Eur J Surg Oncol Date: 2018-12-19 Impact factor: 4.424
Authors: Vincent P Groot; Alex B Blair; Georgios Gemenetzis; Ding Ding; Richard A Burkhart; Jun Yu; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He Journal: Eur J Surg Oncol Date: 2019-04-11 Impact factor: 4.424
Authors: Francis I Macedo; Emily Ryon; Shishir K Maithel; Rachel M Lee; David A Kooby; Ryan C Fields; William G Hawkins; Greg Williams; Ugwuji Maduekwe; Hong J Kim; Syed A Ahmad; Sameer H Patel; Daniel E Abbott; Patrick Schwartz; Sharon M Weber; Charles R Scoggins; Robert C G Martin; Vikas Dudeja; Dido Franceschi; Alan S Livingstone; Nipun B Merchant Journal: Ann Surg Date: 2019-09 Impact factor: 12.969
Authors: Vincent P Groot; Neda Rezaee; Wenchuan Wu; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Lei Zheng; Christopher L Wolfgang; Jin He Journal: Ann Surg Date: 2018-05 Impact factor: 12.969
Authors: Lois A Daamen; Vincent P Groot; Marc G Besselink; Koop Bosscha; Olivier R Busch; Geert A Cirkel; Ronald M van Dam; Sebastiaan Festen; Bas Groot Koerkamp; Nadia Haj Mohammad; Erwin van der Harst; Ignace H J T de Hingh; Martijn P W Intven; Geert Kazemier; Maartje Los; Gert J Meijer; Vincent E de Meijer; Vincent B Nieuwenhuijs; Bobby K Pranger; Mihaela G Raicu; Jennifer M J Schreinemakers; Martijn W J Stommel; Robert C Verdonk; Helena M Verkooijen; Izaak Quintus Molenaar; Hjalmar C van Santvoort Journal: Ann Surg Date: 2022-04-01 Impact factor: 13.787
Authors: Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Ding Ding; Ammar A Javed; Richard A Burkhart; Jun Yu; Inne H Borel Rinkes; I Quintus Molenaar; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Christopher L Wolfgang; Jin He Journal: Ann Surg Oncol Date: 2018-06-14 Impact factor: 5.344
Authors: Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He Journal: Ann Surg Date: 2019-06 Impact factor: 13.787